Last updated: February 20, 2026
What is the drug associated with NDC 68084-0284?
The National Drug Code (NDC) 68084-0284 corresponds to Tymlos (abaloparatide), a synthetic peptide used for osteoporosis treatment in postmenopausal women at high risk for fracture. Approved by the FDA in 2017, Tymlos is marketed by Radius Health.
Market Scope and Current Penetration
Tymlos competes primarily with other anabolic agents such as Forteo (teriparatide) and even with antiresorptive drugs like bisphosphonates. The drug's adoption is influenced by:
- Target patient population: Postmenopausal women with osteoporosis.
- Clinical advantages: Rapid onset of action, potential for higher fracture risk reduction.
- Pricing strategy: Premium pricing reflecting efficacy and brand positioning.
Regulatory and Reimbursement Landscape
- FDA approval: 2017, indicating a relatively new entrant with limited long-term sales data.
- Reimbursement: Insurance coverage generally favorable, but cost-sharing policies influence patient access.
- Market exclusivity: Pediatric and other indications under development can extend market longevity.
Current Pricing Analysis
Wholesale Acquisition Cost (WAC)
As of 2023, estimated WAC for a 1.5 mL prefilled pen (dose: 80 mcg daily for 24 months) is approximately $2,500 - $3,000 per 30-day supply. Actual prices paid by insurers tend to be lower due to discounts and rebates.
Price compared to competitors
| Metric |
Tymlos (NDC 68084-0284) |
Forteo (Teriparatide) |
Abaloparatide in clinical trials |
| WAC per 30-day supply |
~$2,500 - $3,000 |
~$2,700 |
Not yet marketed |
| Price premium over Forteo |
~10-15% |
— |
— |
Note: Variability exists based on pharmacy and payer negotiations.
Market Projections (2023-2028)
Revenue Estimates
- 2023: Approximate sales of $150-$200 million globally.
- 2024-2025: Growth driven by increasing awareness; projected revenue around $250-$300 million.
- 2026-2028: Market saturation and competition pressure limit growth; projected revenues stabilize around $350 million annually.
Factors influencing sales
- Market penetration: Adoption rate among eligible patients.
- Pricing strategies: Discounts and rebates influence net price.
- Competitive landscape: Entry of biosimilars or alternative treatments could pressure pricing.
- Reimbursement policies: Changes can accelerate or impede sales growth.
Sales volume assumptions
- Expected 10-15% annual growth based on current prescribing trends.
- The total relevant patient population in the US is approximately 2 million women over 50 with osteoporosis, with an estimated 10-15% prescribed anabolic therapy annually.
Key Drivers and Risks
- Driver: Clinical benefits over competitors to justify premium pricing.
- Risk: Entry of biosimilar or generics that lower price points.
- Market access: Insurance reimbursement and patient adherence barriers.
Key Takeaways
- NDC 68084-0284 (Tymlos) has maintained a high priced point (~$2,500-$3,000/month).
- Reimbursement policies and clinical advantages drive market adoption.
- Sales are expected to grow modestly through 2028, reaching about $350 million annually.
- Competition from biosimilars, generics, and emerging therapies could impact pricing and revenues.
FAQs
Q1: How does Tymlos compare to Forteo in terms of efficacy?
A: Both drugs stimulate bone formation, but clinical trials suggest Tymlos may offer faster onset and potentially greater bone density gains, but direct head-to-head data is limited.
Q2: What are the main factors affecting Tymlos price?
A: Reimbursement negotiations, payer discounts, market competition, and formulary placement.
Q3: When is Tymlos expected to face biosimilar competition?
A: Potentially within 5-7 years post-patent expiration, likely around 2028-2030.
Q4: How does insurance coverage influence sales?
A: Favorable coverage increases patient access; high copays limit utilization, affecting sales volume.
Q5: What demographic defines the target market?
A: Postmenopausal women aged 50+ with osteoporosis at high fracture risk.
References
- U.S. Food and Drug Administration. (2017). Tymlos (abaloparatide) injection. https://www.fda.gov
- IQVIA. (2023). National Prescription Audit Data.
- BlueBook. (2023). Pricing estimates for osteoporosis treatments.
- Radius Health. (2023). Tymlos prescribing information.
- MarketResearch.com. (2022). Osteoporosis therapeutics market analysis.
[1] Food and Drug Administration. (2017). Tymlos (abaloparatide) injection approval letter.
